Latest Pharmaceuticals News

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.

Cann Group Limited has opened a $6.5 million Share Purchase Plan (SPP) alongside a placement, offering shareholders discounted shares with attaching options as it targets significant revenue growth in FY26.

Clever Culture Systems reports a cashflow positive quarter, expanding its pharmaceutical customer base and launching a new contact plate analysis module that promises to drive recurring revenues.

Arovella Therapeutics reported solid progress in Q1 FY26, moving closer to initiating its first-in-human trial for ALA-101 while securing key patents and maintaining a strong cash position.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir and is progressing regulatory discussions with the FDA to fast-track approval using the Animal Rule, backed by compelling preclinical data.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

Little Green Pharma reported a robust September quarter with revenue exceeding $10 million, driven by growth across all product lines and strong European market performance. The company is poised to benefit from upcoming regulatory reforms and operational efficiencies.

Unith Ltd reports a 32% rise in Q1 FY26 cash receipts and unveils its breakthrough Streaming Avatars technology, alongside a successful $1.85 million capital raise.

Resonance Health reports positive cash flow and significant progress in its clinical trials and Software-as-a-Medical Device business, setting the stage for growth in new international markets.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Sprintex Limited has landed US$321,000 in new purchase orders from its exclusive Indian distributor Euroteck, following the launch of its advanced GR Series Jet Blowers and a key commissioning at Delhi’s Kondli wastewater plant. This momentum underscores Sprintex’s growing footprint in India’s expanding wastewater treatment market.